Optiver Holding’s BioCryst Pharmaceuticals BCRX Stock Holding History

Optiver Holding’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-302	Closed	-$2.88K	–	2796
2026 Q1	$2.88K	Sell	302 -181	-37%	-$1.41K	﹤0.01%	1688
2025 Q4	$3.77K	Sell	483 -807	-63%	-$5.83K	﹤0.01%	1575
2025 Q3	$9.79K	Sell	1,290 -4,292	-77%	-$35.7K	﹤0.01%	1316
2025 Q2	$50K	Buy	5,582 +5,073	+997%	+$47.2K	﹤0.01%	621
2025 Q1	$3.82K	Buy	509 +460	+939%	+$3.71K	﹤0.01%	1147
2024 Q4	$368	Buy	+49	New	+$372	﹤0.01%	1014
2024 Q3	–	Sell	-936	Closed	-$5.78K	–	951
2024 Q2	$5.78K	Buy	+936	New	+$5.17K	﹤0.01%	782

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Optiver Holding's BCRX Position: Q2 2026 in Review

Optiver Holding sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 302 shares — an estimated $2.88K sold.

Optiver Holding first reported a position in BCRX in Q2 2024 and held it in 7 quarters. The position peaked at $50K in Q2 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Optiver Holding reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Optiver Holding sold 302 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $2.88K.
Optiver Holding first reported a position in BioCryst Pharmaceuticals in Q2 2024 and held it in 7 quarters.
Optiver Holding's BioCryst Pharmaceuticals position peaked at $50K in Q2 2025.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.